Eric Jonasch, MD | Authors


CheckMate 9ER: Real World and Health-Related Quality of Life Outcomes

December 13, 2022

Dr Jonasch shares his perspective on CheckMate 9ER in the real-world setting and discusses the trial’s health-related quality-of-life outcomes data investigating nivolumab plus cabozantinib in advanced renal cell carcinoma treatment.

CheckMate 9ER: Long-Term Follow-Up Data

December 13, 2022

Dr Eric Jonasch reviews key efficacy and safety outcomes of the long term follow-up data from CheckMate 9ER and discusses the rationale for evaluating cabozantinib plus nivolumab in patients with advanced RCC.